Fallopian Tube Cancer Clinical Trials

27 studies are recruiting for fallopian tube cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

   This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   OU Health, Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   4 in total

   Run by

   Imunon

   See if you can join NCT05739981 on ClinicalTrials.gov

2. Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

   This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Advent Health, Orlando, Florida

   Locations

   9 in total

   Run by

   Imunon

   See if you can join NCT06915025 on ClinicalTrials.gov

3. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

   This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other ant…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   56 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06787612 on ClinicalTrials.gov

4. A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham, Alabama

   Locations

   70 in total

   Run by

   AbbVie

   See if you can join NCT06890338 on ClinicalTrials.gov

5. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

   The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama at Birmingham ( Site 0006), Birmingham, Alabama

   Locations

   196 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06824467 on ClinicalTrials.gov

6. Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

   The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with pla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama

   Locations

   33 in total

   Run by

   Genelux Corporation

   See if you can join NCT05281471 on ClinicalTrials.gov

7. A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

   This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   28 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT04590326 on ClinicalTrials.gov

8. A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

   This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The first medical center of PLA general hospital, Beijing, Beijing Municipality

   Locations

   17 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06792552 on ClinicalTrials.gov

9. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

   This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USOR HonorHealth, Phoenix, Arizona

   Locations

   66 in total

   Run by

   Genmab

   See if you can join NCT05579366 on ClinicalTrials.gov

10. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    82 in total

    Run by

    Artios Pharma Ltd

    See if you can join NCT04657068 on ClinicalTrials.gov

11. Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

    The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy. If a participant is a good fit for the study, and they enroll i…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    CU Medicine Clinics, Aurora, Colorado

    Locations

    2 in total

    Run by

    University of Colorado, Denver

    See if you can join NCT06856499 on ClinicalTrials.gov

12. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    004, Birmingham, Alabama

    Locations

    49 in total

    Run by

    Corcept Therapeutics

    See if you can join NCT06906341 on ClinicalTrials.gov

13. An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

    The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.

    Stage

    Phase 2

    Ages

    18 to 100

    Site

    City of Hope Lennar, Irvine, California

    Locations

    6 in total

    Run by

    University of Colorado, Denver

    See if you can join NCT05887609 on ClinicalTrials.gov

14. A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

    The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS or IDS and also if it's better than the standard-of-car…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05429970 on ClinicalTrials.gov

15. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

    Locations

    26 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

16. Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

    This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    9 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05287451 on ClinicalTrials.gov

17. ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

    This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

    Run by

    Alexander B Olawaiye, MD

    See if you can join NCT05071937 on ClinicalTrials.gov

18. A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMG…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Holy Name Medical Center /ID# 279017, Teaneck, New Jersey

    Locations

    16 in total

    Run by

    AbbVie

    See if you can join NCT07024784 on ClinicalTrials.gov

19. Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

    This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer. The name of the study intervention involved in this study is: -implant…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT04701645 on ClinicalTrials.gov

20. A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

    This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site 0264, Aurora, Colorado

    Locations

    24 in total

    Run by

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    See if you can join NCT04516447 on ClinicalTrials.gov

21. Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

    Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard su…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06290193 on ClinicalTrials.gov

22. A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

    This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. Th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    5 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT06469281 on ClinicalTrials.gov

23. CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

    A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic Hospital, Phoenix, Arizona

    Locations

    66 in total

    Run by

    TORL Biotherapeutics, LLC

    See if you can join NCT06690775 on ClinicalTrials.gov

24. Study of AVZO-021 in Patients With Advanced Solid Tumors

    This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    13 in total

    Run by

    Avenzo Therapeutics, Inc.

    See if you can join NCT05867251 on ClinicalTrials.gov

25. Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

    This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

    Locations

    2 in total

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06617923 on ClinicalTrials.gov